Molekulinės biotechnologijos centras, UAB - financials and debts
Company age: 7 y. 6 mo.
Molekulinės biotechnologijos centras - Company finances
- The company is late in submitting financial data for the previous financial year.
- Latest financial data up to 2024-12-31.
|
EUR
|
2019
From: 2019-03-27
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | - | 13,680 | 216,903 | 276,721 | 274,029 | 323,448 |
| Profit before tax | - | - | - | - | - | - |
| Net profit | -54 | -2,223 | 7,864 | 10,112 | 19,397 | 29,714 |
| Equity | 2,446 | 223 | 8,087 | 12,861 | 22,147 | 51,860 |
| Liabilities | 28 | 3,702 | 82,125 | 28,944 | 92,208 | 68,352 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 120,212 |
| Current assets | 2,474 | 3,925 | 90,212 | 41,805 | 114,217 | 0 |
| Total assets | 2,474 | 3,925 | 90,212 | 41,805 | 114,217 | 120,212 |
|
Taxes paid
|
||||||
| Social insurance contributions | - | - | - | - | 15,392 | 13,328 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | - | +1485.5% | +27.6% | -1.0% | +18.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -2.2% | -56.6% | 8.7% | 24.2% | 17.0% | 24.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -2.2% | -996.9% | 97.2% | 78.6% | 87.6% | 57.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | -16.3% | 3.6% | 3.7% | 7.1% | 9.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 16.6 | 10.2 | 2.3 | 4.2 | 1.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 13,680 | 70,348 | 63,859 | 68,507 | 82,582 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Molekulinės biotechnologijos centras - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-01-16 | 2024-02-07 | 0.34 |
| 2023-12-18 | 2023-12-28 | 0.34 |
| 2023-11-16 | 2023-12-07 | 0.34 |
| 2023-10-17 | 2023-11-07 | 0.34 |
| 2023-09-18 | 2023-10-05 | 0.34 |
| 2023-07-28 | 2023-08-07 | 0.34 |
| 2023-07-26 | 2023-07-27 | 0.01 |
| 2023-07-24 | 2023-07-25 | 0.36 |
| 2023-07-18 | 2023-07-23 | 0.01 |
| 2023-06-16 | 2023-07-06 | 0.01 |
| 2023-05-16 | 2023-06-07 | 0.01 |
| 2023-05-02 | 2023-05-07 | 0.01 |
| 2023-04-18 | 2023-04-28 | 0.01 |
| 2023-03-16 | 2023-04-06 | 0.01 |
| 2023-02-06 | 2023-02-07 | 0.01 |
| 2023-01-17 | 2023-02-03 | 0.01 |
| 2022-12-16 | 2022-12-29 | 0.01 |
| 2022-11-21 | 2022-12-07 | 0.01 |
| 2022-11-17 | 2022-11-18 | 0.01 |
| 2022-10-18 | 2022-11-07 | 0.01 |
Molekulinės biotechnologijos centras - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.